Polar Capital Holdings Plc Boosts Stock Position in Roivant Sciences Ltd. $ROIV

Polar Capital Holdings Plc raised its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 37.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,690,124 shares of the company’s stock after purchasing an additional 731,389 shares during the period. Polar Capital Holdings Plc’s holdings in Roivant Sciences were worth $58,376,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. TD Asset Management Inc raised its position in shares of Roivant Sciences by 94.7% in the third quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock valued at $4,784,000 after buying an additional 153,800 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Roivant Sciences during the third quarter worth approximately $877,000. HighVista Strategies LLC boosted its position in Roivant Sciences by 61.4% during the third quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock worth $1,496,000 after acquiring an additional 37,590 shares during the last quarter. Neo Ivy Capital Management grew its stake in Roivant Sciences by 229.6% in the 3rd quarter. Neo Ivy Capital Management now owns 237,392 shares of the company’s stock worth $3,592,000 after acquiring an additional 165,362 shares during the period. Finally, Capricorn Fund Managers Ltd grew its stake in Roivant Sciences by 124.4% in the 4th quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock worth $9,667,000 after acquiring an additional 247,000 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Trading Up 1.3%

Shares of Roivant Sciences stock opened at $30.41 on Wednesday. The business’s fifty day moving average price is $29.03 and its 200 day moving average price is $26.15. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $32.79. The stock has a market capitalization of $21.87 billion, a P/E ratio of -50.68 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the prior year, the firm posted ($0.29) earnings per share. As a group, sell-side analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Leerink Partners set a $42.00 target price on Roivant Sciences in a research note on Thursday, May 21st. Sanford C. Bernstein started coverage on Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target for the company. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Citigroup increased their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $33.59.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at $48,827,417.01. The trade was a 11.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Matthew Gline sold 289,774 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the sale, the chief executive officer owned 16,736,116 shares of the company’s stock, valued at approximately $488,025,142.56. This represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 703,312 shares of company stock worth $20,805,883. 10.80% of the stock is currently owned by company insiders.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.